Trial Profile
A randomized open-label study comparing the efficacy and safety of sirolimus combined with daclizumab, mycophenolate and corticosteroids vs cyclosporine, mycophenolate and corticosteroids in renal allograft recipients receiving kidneys from older donors.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Aug 2010
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary) ; Daclizumab (Primary) ; Sirolimus (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Sponsors Wyeth
- 15 Aug 2010 Results presented at the 23rd International Congress of the Transplantation Society.
- 15 Sep 2009 Actual number of patients (61) added as reported by ClinicalTrials.gov.
- 15 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.